Literature DB >> 24727767

Acquiring orphans.

Rogier Rooswinkel1, Geert-Jan Mulder1, Sander van Deventer2.   

Abstract

Mesh：

Year:  2014        PMID： 24727767     DOI： 10.1038/nbt.2836

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

1.  Orphan drug development: an economically viable strategy for biopharma R&D.

Authors:  Kiran N Meekings; Cory S M Williams; John E Arrowsmith
Journal:  Drug Discov Today       Date:  2012-02-17       Impact factor: 7.851

2.  Pricing for orphan drugs: will the market bear what society cannot?

Authors:  Brian P O'Sullivan; David M Orenstein; Carlos E Milla
Journal:  JAMA       Date:  2013-10-02       Impact factor: 56.272

3.  The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?

Authors:  Olivier Wellman-Labadie; Youwen Zhou
Journal:  Health Policy       Date:  2009-12-29       Impact factor: 2.980

4.  2012 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

5.  Building for big pharma.

Authors:  Asiya Giniatullina; Marco Boorsma; Geert-Jan Mulder; Sander van Deventer
Journal:  Nat Biotechnol       Date:  2013-04       Impact factor: 54.908
  5 in total
  2 in total

1.  Valuation and Returns of Drug Development Companies: Lessons for Bioentrepreneurs and Investors.

Authors:  Daniel Tobias Michaeli; Hasan Basri Yagmur; Timur Achmadeev; Thomas Michaeli
Journal:  Ther Innov Regul Sci       Date:  2022-01-11       Impact factor: 1.778

2.  Value drivers of development stage biopharma companies.

Authors:  Daniel Tobias Michaeli; Hasan Basri Yagmur; Timur Achmadeev; Thomas Michaeli
Journal:  Eur J Health Econ       Date:  2022-01-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.